Skip to search formSkip to main contentSkip to account menu

DI-Leu16-IL2 Immunocytokine

Known as: De-Immunized Anti-CD20-IL-2 Immunocytokine DI-Leu16-IL-2 
A recombinant fusion protein consisting of de-immunized and humanized anti-CD20 monoclonal antibody Leu16 fused to human cytokine interleukin-2 (IL2… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
ABSTRACT We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises… 
Highly Cited
2016
Highly Cited
2016
Interest in combining radiotherapy and immune checkpoint therapy is growing rapidly. In this study, we explored a novel… 
Highly Cited
2013
Highly Cited
2013
Systemic high-dose IL2 promotes long-term survival in a subset of metastatic melanoma patients, but this treatment is accompanied… 
2000
2000
The induction of tumor-protective immunity against malignancies remains a major challenge in cancer immunotherapy. A novel… 
1998
1998
Immunocytokines are antibody-cytokine fusion proteins that combine the unique targeting ability of antibodies with the… 
Highly Cited
1997
Highly Cited
1997
We examined the role of the cellular localization of antigen on the immune response after DNA immunization of mice with three… 
Highly Cited
1985
Highly Cited
1985
To determine the changes in patterns of 17 beta-estradiol and progesterone levels underlying abnormal cycles in bitches immunized…